<?xml version='1.0' encoding='utf-8'?>
<document id="27733479"><sentence text="A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors."><entity charOffset="109-120" id="DDI-PubMed.27733479.s1.e0" text="Dacomitinib" /><entity charOffset="125-136" id="DDI-PubMed.27733479.s1.e1" text="Figitumumab" /><pair ddi="false" e1="DDI-PubMed.27733479.s1.e0" e2="DDI-PubMed.27733479.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27733479.s1.e0" e2="DDI-PubMed.27733479.s1.e1" /></sentence><sentence text="Purpose: This phase I, open-label, single-arm trial assessed the safety and tolerability of dacomitinib-figitumumab combination therapy in patients with advanced solid tumors" /><sentence text="Experimental Design: A standard 3 + 3 dose escalation/de-escalation design was utilized" /><sentence text=" Starting doses were figitumumab 20 mg/kg administered intravenously once every 3 weeks and dacomitinib 30 mg administered orally once daily"><entity charOffset="92-103" id="DDI-PubMed.27733479.s4.e0" text="dacomitinib" /></sentence><sentence text=" We also performed an independent study of the combination in patient-derived xenograft (avatar mouse) models of adenoid cystic carcinoma" /><sentence text="Results: Of the 74 patients enrolled, the most common malignancies were non-small cell lung cancer (24" /><sentence text="3%) and colorectal cancer (14" /><sentence text="9%)" /><sentence text=" The most common treatment-related adverse events in the 71 patients who received treatment across five dose levels were diarrhea (59" /><sentence text="2%), mucosal inflammation (47" /><sentence text="9%), and fatigue and acneiform dermatitis (45" /><sentence text="1% each)" /><sentence text=" The most common dose-limiting toxicity was mucosal inflammation" /><sentence text=" Dosing schedules of dacomitinib 10 or 15 mg daily plus figitumumab 20 mg/kg every 3 weeks after a figitumumab loading dose were tolerated by patients over multiple cycles and considered recommended doses for further evaluation"><entity charOffset="21-32" id="DDI-PubMed.27733479.s14.e0" text="dacomitinib" /></sentence><sentence text=" Objective responses were seen in patients with adenoid cystic carcinoma, ovarian carcinoma, and salivary gland cancer" /><sentence text=" Pharmacokinetic analysis did not show any significant drug-drug interaction" /><sentence text=" In the adenoid cystic carcinoma xenograft model, figitumumab exerted significant antitumor activity, whereas dacomitinib did not" /><sentence text=" Figitumumab-sensitive tumors showed downregulation of genes in the insulin-like growth factor receptor 1 pathway" /><sentence text="Conclusions: Dacomitinib-figitumumab combination therapy was tolerable with significant dose reductions of both agents to less than the recommended single-agent phase II dose of each drug" /><sentence text=" Preliminary clinical activity was demonstrated in the potential target tumor adenoid cystic carcinoma" /><sentence text=" Clin Cancer Res; 23(5); 1177-85" /><sentence text=" Â©2016 AACRSee related commentary by Sundar et al" /><sentence text=", p" /><sentence text=" 1123" /><sentence text="" /></document>